Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
| Revenues: |
| Outside Mainland China | 8,473.8 | 145.0 | 18.9 | 14.5 | | | | |
| EPI | 10,552.1 | 96.8 | 6.9 | 10.4 | | | | |
| Export | 8,473.8 | 145.0 | 18.9 | 14.5 | | | | |
| Private Pay | 349.1 | 268.8 | 220.2 | 204.8 | | | | |
| Total revenues [+] | 19,374.9 | 510.6 | 246.1 | 229.7 | 174.3 | 72.4 | 65.8 | 62.8 |
| Products | 19,374.9 | 510.6 | 246.1 | 229.7 | | | 67.4 | 62.9 |
| Grants | | | | | | | -1.6 | -0.1 |
| Revenue growth [+] | 3694.4% | 107.5% | 7.1% | 31.7% | 140.7% | 10.1% | 4.7% | -12.5% |
| Outside Mainland China | 5743.8% | 665.6% | 30.4% | | | | | |
| EPI | 10801.0% | 1303.7% | -33.4% | | | | | |
| Export | 5743.8% | 665.6% | 30.4% | | | | | |
| Private Pay | 29.9% | 22.1% | 7.5% | | | | | |
| Mumps Vaccines | | | | | 249.5% | | | |
| Cost of goods sold | 1,072.2 | 67.2 | 32.5 | 24.7 | 20.2 | 22.4 | 18.4 | 15.5 |
| Gross profit | 18,302.7 | 443.4 | 213.6 | 204.9 | 154.1 | 50.0 | 47.4 | 47.4 |
| Gross margin | 94.5% | 86.8% | 86.8% | 89.2% | 88.4% | 69.1% | 72.0% | 75.4% |
| Selling, general and administrative | 591.2 | 176.5 | 121.5 | 137.0 | 87.4 | 42.0 | 37.5 | 34.3 |
| Research and development | 155.0 | 48.8 | 24.3 | 21.9 | 20.5 | 12.6 | 9.5 | 10.9 |
| Other operating expenses | 1.3 | 2.2 | -1.3 | 0.5 | 0.8 | -5.6 | -3.3 | 0.1 |
| EBITDA [+] | 17,639.8 | 219.8 | 73.7 | | | | | |
| EBITDA growth | 7926.5% | 198.1% | 62.2% | 0.0% | 4529.2% | -73.6% | 89.9% | -80.5% |
| EBITDA margin | 91.0% | 43.0% | 30.0% | 19.8% | 26.1% | 1.4% | 5.7% | 3.1% |
| Depreciation | 84.4 | 3.7 | 4.6 | | | | | |
| EBITA | 17,555.4 | 216.1 | 69.2 | 45.5 | 45.5 | 1.0 | 3.7 | 2.0 |
| EBITA margin | 90.6% | 42.3% | 28.1% | 19.8% | 26.1% | 1.4% | 5.7% | 3.1% |
| Amortization of intangibles | 0.2 | 0.1 | | | | | | |
| EBIT [+] | 17,555.2 | 216.0 | 69.2 | 45.5 | 45.5 | 1.0 | 3.7 | 2.0 |
| EBIT growth | 8028.5% | 212.3% | 52.1% | 0.0% | 4529.2% | -73.6% | 89.9% | -80.5% |
| EBIT margin | 90.6% | 42.3% | 28.1% | 19.8% | 26.1% | 1.4% | 5.7% | 3.1% |
| Non-recurring items [+] | 2.0 | 0.3 | 0.6 | 0.2 | 0.0 | 0.5 | 0.0 | 0.1 |
| Asset impairment | | | | | | | | 0.1 |
| Loss (gain) on sale of assets | 1.0 | 0.2 | 0.3 | 0.1 | 0.0 | 0.5 | 0.0 | |
| Interest income, net [+] | 99.7 | 0.5 | 1.3 | 0.9 | -0.4 | -1.0 | -0.8 | -0.7 |
| Interest expense | 2.8 | 1.5 | 0.7 | 1.1 | 1.6 | 1.7 | 1.9 | 3.4 |
| Interest income | 102.6 | 1.9 | 2.0 | 2.0 | 1.2 | 0.7 | 1.2 | 2.7 |
| Other income (expense), net | -89.9 | 0.5 | 0.9 | 0.3 | 0.0 | 0.1 | -0.2 | 1.2 |
| Pre-tax income | 17,563.0 | 216.6 | 70.8 | 46.6 | 45.0 | -0.4 | 2.8 | 2.3 |
| Income taxes | 3,104.1 | 31.4 | 5.6 | 10.5 | 8.3 | 2.7 | 3.0 | 2.1 |
| Tax rate | 17.7% | 14.5% | 7.9% | 22.5% | 18.5% | | 108.3% | 88.1% |
| Minority interest | 5,991.4 | 74.8 | 20.3 | 14.3 | 10.9 | -0.1 | 0.5 | 0.3 |
| Net income | 8,461.5 | 104.4 | 39.8 | 21.8 | 25.8 | -0.6 | -1.4 | -1.5 |
| Net margin | 43.7% | 20.4% | 16.2% | 9.5% | 14.8% | -0.8% | -2.2% | -2.4% |
| |
| Basic EPS [+] | $85.20 | $1.06 | $0.42 | $0.34 | $0.45 | ($0.01) | ($0.03) | ($0.03) |
| Growth | 7974.6% | 151.5% | 24.7% | -25.6% | -4423.6% | -58.4% | -7.6% | -120.2% |
| Diluted EPS [+] | $74.22 | $0.92 | $0.36 | $0.34 | $0.45 | ($0.01) | ($0.03) | ($0.03) |
| Growth | 7984.0% | 153.0% | 8.2% | -25.8% | -4418.5% | -58.4% | -6.9% | -120.2% |
| |
| Dividends per share | $18.89 | | | | | | | |
| |
| Shares outstanding (basic) [+] | 99.3 | 98.9 | 94.9 | 64.7 | 57.0 | 56.9 | 56.3 | 55.7 |
| Growth | 0.4% | 4.2% | 46.6% | 13.5% | 0.1% | 1.1% | 1.1% | 0.7% |
| Shares outstanding (diluted) [+] | 114.0 | 113.7 | 109.7 | 65.0 | 57.1 | 56.9 | 56.3 | 56.1 |
| Growth | 0.3% | 3.6% | 68.8% | 13.8% | 0.3% | 1.1% | 0.4% | 0.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|